Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products.

ABSTRACT: Gene expression plasticity is central for macrophages' timely responses to cues from the microenvironment permitting phenotypic adaptation from pro-inflammatory (M1) to wound healing and tissue-regenerative (M2, with several subclasses). Regulatory macrophages are a distinct macrophage type, possessing immunoregulatory, anti-inflammatory, and angiogenic properties. Due to these features, regulatory macrophages are considered as a potential cell therapy product to treat clinical conditions, e.g., non-healing diabetic foot ulcers. In this study we characterized two differently manufactured clinically relevant regulatory macrophages, programmable cells of monocytic origin and comparator macrophages (M1, M2a and M0) using flow-cytometry, RT-qPCR, phagocytosis and secretome measurements, and RN

SUBMITTER: Gurvich OL 

PROVIDER: S-EPMC7441152 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature